Redwood City, California-based Revolution Medicines Inc, a developer of medicines for cancer patients, has secured $100 million in Series C financing. The investors included Boxer Capital of the Tavistock Group, Cormorant Capital, Deerfield Management, Fidelity Management & Research Company, Vivo Capital, Biotechnology Value Fund, Nextech Invest, Schroder Adveq, The Column Group, Third Rock Ventures and Casdin Capital.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: